Skip to main content

Table 2 Background characteristics according to HCV RNA positivity

From: Change in hepatitis C virus positivity among needle-stick injury source patients: a 10-year experience in a Japanese tertiary hospital

Variables

Between 2009 and 2014

(n = 102)

Between 2015 and 2019

(n = 48)

HCV-RNA

Positive

(n = 78)

HCV-RNA

Negative

(n = 24)

p-value

HCV-RNA

Positive

(n = 23)

HCV-RNA

Negative

(n = 25)

p-value

Age (years)

71.7 ± 10.6

63.8 ± 14.5

0.0122*

71.4 ± 8.8

69.4 ± 13.5

0.8123

Gender, male – no. (%, 95CI)

44 (56.4, 45.4–66.9)

17 (70.8, 50.8–85.1)

0.2412

11 (47.8, 29.2–67.0)

16 (64.0, 44.5–79.8)

0.3830

HCV-Ab titera

9.8 ± 0.6

6.9 ± 2.9

<  0.0001*

10.0 ± 0.1

7.3 ± 3.4

0.0006*

Department, LDs – no. (%, 95CI)

46 (59.0, 47.9–69.2)

8 (33.3, 18.0–53.3)

0.0358*

14 (60.9, 40.8–77.8)

7 (28.0, 14.3–47.6)

0.0405*

Antiviral therapyb

 -Interferon, Yes – no. (%, 95CI)

27 in 75

(36.0, 26.1–47.3)

12 in 21

(57.1, 36.5–75.5)

0.1302

7 in 22

(31.8, 16.4–52.7)

10 in 23

(43.5, 25.6–63.2)

0.5420

 -DAAs, Yes – no. (%, 95CI)

–

–

–

2 in 22

(9.1, 2.5–27.8)

9 in 23

(39.1, 22.2–59.2)

0.0351*

  1. Values are expressed as means ± SD unless otherwise stated
  2. HCV hepatitis C virus, LDs liver disease-related departments, CI confidence interval
  3. aAbout HCV-Ab titer, between 2009 and 2014, 1 HCV RNA-negative patient had no result documented in the medical record
  4. bAbout histories of antiviral therapy, between 2009 and 2014, 3 HCV RNA-positive and HCV RNA-negative patients each had no treatment history documented in the medical record. Between 2015 and 2019, 1 HCV RNA-positive and 2 HCV RNA-negative patients had no treatment history documented in their medical record. In the era after DAAs, 2 HCV RNA-positive and HCV RNA-negative patients each were treated with both IFN-based therapies and DAAs. Total number of each column was provided if there was missing data
  5. *p < 0.05
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us